Corporate News • Drug Discovery
REPROCELL’s Corporate News
REPROCELL, IBM and STFC harness the power of AI in drug discovery and precision medicine
31 August 2022 • Drug Discovery
New collaboration at Hartree National Centre for Digital Innovation combines REPROCELL’s tests of drug efficacy in human living tissues with IBM expertise in artificial intelligence and machine learning.
Read more →Preclinical studies by REPROCELL give COPD drug a final boost before clinical trials
17 August 2022 • Drug Discovery
Glasgow UK - 17 August 2022: A drug being developed for the treatment of severe asthma and COPD has passed an important milestone. Scientists at REPROCELL compared the effects of the compound, RCD405, with drugs that are currently used to treat respiratory disease by assessing the effects of the drug ex vivo in human living bronchi.
Read more →Life science after lockdown - SPS returns for 2022
15 August 2022 • Drug Discovery
Next month, the Safety Pharmacology Society (SPS) will be hosting its first in-person meeting since 2019. Now in its 22nd year, this dynamic forum is known for its global networking opportunities and events promoting the best practices in safety pharmacology.
Read more →REPROCELL co-author paper with IBM showcasing a novel ML driven precision medicine strategy for drug development
8 March 2022 • Drug Discovery
Glasgow UK - 25 February 2022: REPROCELL, in collaboration with researchers at IBM and the Precision Medicine Scotland Innovation Centre, have co-authored a publication aiming to improve precision medicine strategies.
Read more →REPROCELL spotlights the power of smarter biospecimens in new global publication
21 January 2022 • Drug Discovery
Glasgow UK - 21 January 2022: REPROCELL has published an article highlighting the power of human biospecimens in the latest issue of European Biopharmaceutical Review (EBR). The piece, titled Dynamizing Biomarker R&D with Smarter Biospecimens, explains why quality biospecimens are essential to translational biomarker research.
Read more →Hoth Therapeutics Extends Partnership Agreement with REPROCELL
25 October 2021 • Drug Discovery
GLASGOW, October 25, 2021: Hoth Therapeutics, Inc. (NASDAQ: HOTH) has extended its partnership agreement with REPROCELL to assess the effect of the HT-003 therapeutic platform in inflammatory bowel disease (IBD). Fresh explants of ulcerative colitis and Crohn’s disease tissues will be used to investigate the therapeutic potential of Hoth's HT-003 drugs. All testing will be performed at REPROCELL's Centre for Predictive Drug Discovery.
Read more →REPROCELL highlights the power of human fresh tissue in global publication
5 July 2021 • Drug Discovery
Glasgow, UK: REPROCELL employees, Zara Puckrin and Graeme Macluskie, have published a headline article in the latest issue of European Biopharmaceutical Review (EBR).
Read more →Hoth Therapeutics Executes Partnership Agreement with REPROCELL to Assess the Effect of HT-003 Therapeutic Platform on Inflammatory Bowel Disease
15 March 2021 • Drug Discovery
NEW YORK, March 11, 2021/PR Newswire/ Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced it has executed a partnership agreement with REPROCELL, a contract research organization (CRO), providing a unique combination of products and services to power translational research, to assess the effect of the HT-003 therapeutic platform on tissue from ulcerative colitis and Crohn’s disease patients. Fresh explants of ulcerative colitis and Crohn’s disease tissues obtained from surgical resection will be used as the test systems to investigate the therapeutic potential of the HT-003 drugs via measurement of key biomarkers for these diseases. All testing will be performed by REPROCELL.
Read more →eTheRNA-led international consortium starts preclinical studies of cross-strain protective COVID-19 mRNA vaccine for high risk populations
16 July 2020 • Drug Discovery
March 19, 2020
Read more →